Greenwich LifeSciences (GLSI) Stock Price, News & Analysis

Company Overview

Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapies. The company’s lead product candidate is nelipepimut-S (NPS), a peptide-based immunotherapy designed to stimulate an immune response against HER2/neu, a protein expressed in several types of cancer.

Greenwich LifeSciences has primarily studied NPS as an adjuvant treatment for patients with HER2-expressing breast cancer, including in combination with trastuzumab. Its clinical development program has included the Phase III PRESENT trial, which evaluated NPS in patients with early-stage breast cancer who had completed standard surgery and other indicated treatments. NPS remains an investigational therapy and is not an approved commercial product.

The company was founded to advance NPS-based cancer treatments and is headquartered in Houston, Texas. Greenwich LifeSciences is led by Chief Executive Officer Snehal Patel, who has been associated with the company since its formation. Its activities have centered on clinical research and development in the United States, with no broad commercial product portfolio publicly identified.

Key Stats

• Today's Range: $16.60 to $18.25
• 50-Day Range: $12.77 to $19.48
• 52-Week Range: $7.78 to $34.10
• Volume: 175,415 shs
• Average Volume: 111,705 shs
• Market Capitalization: $249.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $69.00
• Consensus Rating: Hold

Greenwich LifeSciences Stock Analysis - MarketRank™

Greenwich LifeSciences scored higher than 44% of companies evaluated by MarketBeat, and ranked 589th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Greenwich LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Greenwich LifeSciences has a consensus price target of $69.00, representing about 306.4% upside from its current price of $16.98.

Amount of Analyst Coverage

Greenwich LifeSciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Greenwich LifeSciences are expected to grow in the coming year, from ($1.38) to ($1.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Greenwich LifeSciences is -11.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Greenwich LifeSciences is -11.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Greenwich LifeSciences has a P/B Ratio of 566.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.90% of the float of Greenwich LifeSciences has been sold short.

Short Interest Ratio / Days to Cover

Greenwich LifeSciences has a short interest ratio ("days to cover") of 19.78, which indicates bearish sentiment.

Change versus previous month

Short interest in Greenwich LifeSciences has recently decreased by 1.80%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Greenwich LifeSciences does not currently pay a dividend.

Dividend Growth

Greenwich LifeSciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

3 people have added Greenwich LifeSciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $76,618.00 in company stock, which represents 0.0307% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Greenwich LifeSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $76,618.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

51.47% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

4.16% of the stock of Greenwich LifeSciences is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GLSI
• CIK: 1799788
• Web: www.greenwichlifesciences.com
• Phone: 832-819-3232
• Fax: N/A
• Employees: 13
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Greenwich LifeSciences: $69.00
• High Price Target: $69.00
• Low Price Target: $69.00
• Potential Upside/Downside: +306.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.36 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -793.81%
• Return on Assets: -295.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.54
• Quick Ratio: 1.54

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.03 per share
• Price / Book: 566.00

Miscellaneous

• Outstanding Shares: 14,680,000
• Free Float: 7,123,000
• Market Cap: $249.27 million
• Optionable: Not Optionable
• Beta: 1.46